BOOST Pharma announces positive top-line results from Phase I/II BOOSTB4 study, demonstrating over 75% reduction of fracture rates in children born with rare bone disease Osteogenesis Imperfecta (OI)
Top-line clinical data show that treatment is safe and well tolerated
Over 75% reduction in bone fracture rate observed
Latest clinical results and development program to be discussed with relevant regulatory authorities
September 24, 2024
BOOST Pharma announces positive top-line results from Phase I/II BOOSTB4 study
< Back to Updates